Axsome Therapeutics CEO Completes Planned $6 Million Options Sale Ahead of Pivotal FDA Decision

Company Overview - Axsome Therapeutics is a biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) conditions, with a strategy centered on advancing a diversified pipeline of late-stage clinical assets addressing high unmet medical needs [1] - The company's pipeline includes AXS-05 for major depressive disorder and Alzheimer's disease agitation, AXS-07 for migraine, AXS-12 for narcolepsy, and AXS-14 for fibromyalgia [2] Recent Transactions - CEO Herriot Tabuteau exercised and immediately sold 32,410 common shares in an open-market transaction on February 2, 2026, as disclosed in the SEC Form 4 filing [5] - The sale was a result of exercising options that were set to expire, with all shares sold immediately on the open market, reducing direct holdings by 81.76% to only 7,229 shares [4][6] Financial Performance - Axsome reported strong full-year 2025 net product revenue growth of 66% year over year, driven by its marketed CNS portfolio [7] - The company is approaching a pivotal regulatory moment, with the FDA granting Priority Review to AXS-05 for Alzheimer's disease agitation, and a decision expected by April 30, 2026 [7] Investment Considerations - Axsome Therapeutics may appeal to growth-oriented investors comfortable with biotech risk, as it has cleared the hurdle of building real commercial revenue while still having meaningful pipeline upside [8] - Key factors to monitor include the April FDA decision on AXS-05 for Alzheimer's agitation, continued prescription momentum for Auvelity, and whether accelerating revenue can close the gap to profitability [8]